Skip to main
BVS

Bioventus (BVS) Stock Forecast & Price Target

Bioventus (BVS) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bioventus Inc. reported a strong quarterly performance, with its surgical solutions segment generating $55.5 million in revenue, reflecting a growth of 10.3% when excluding the impact of divestitures, driven by effective sales execution of the Exogen bone stimulation system. The company's pain treatments business also exhibited robust performance, achieving $79.7 million in revenue and expected to benefit from increased investments targeting growth in various areas including peripheral nerve stimulation and ultrasound technologies. Management projects that both the surgical solutions segment will grow at a low-double-digit percentage in 2026 and significant improvements in adjusted EBITDA margins are anticipated between 2025 and 2030, indicating a positive growth trajectory for the company.

Bears say

Bioventus Inc's financial outlook appears negative due to anticipated elevated investment levels in key growth areas, which may result in stable to declining adjusted EBITDA margins in the upcoming years. The company experienced a substantial decline in restorative therapies revenue by 26.0%, alongside a decrease in international revenue of 8.6%, indicating potential challenges in revenue generation. Additionally, the gross margin fell short of expectations, registering at 68.9% against an estimate of 69.5%, further underscoring underlying financial pressures.

Bioventus (BVS) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioventus (BVS) Forecast

Analysts have given Bioventus (BVS) a Buy based on their latest research and market trends.

According to 3 analysts, Bioventus (BVS) has a Buy consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioventus (BVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.